Mild cognitive impairment: what's next?

Tabeeva, G. R.

doi:10.17116/jnevro2019119101103

Cited by 1 publication

(1 citation statement)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the improvement of pharmacotherapy of vascular cognitive impairments, the majority of the drugs used today are either insufficiently efficient or cause a number of side effects that limit their long-term and widespread use (Sun 2018, Van der Flier et al 2018, Tabeeva 2019b. Therefore, the search for new drugs for the prevention and treatment of vascular cognitive disorders continues to be relevant.…”

Section: Introductionmentioning

confidence: 99%

Antiamnestic effect of new nicotinic acid derivatives

Yasnetsov¹,

Kaurova²,

Skachilova³

et al. 2021

RRP

View full text Add to dashboard Cite

Introduction: The search for new drugs for the prevention and treatment of vascular cognitive disorders continues to be a relevant task of pharmacology. In this regard, the aim of this work is to study the antiamnestic effect of five new nicotinic acid derivatives in comparison with the well-known drug mexidol (ethylmethylhydroxypyridine succinate) in animals. Materials and methods: The experiments were carried out on white male mice using conditioned passive avoidance reflex (CPAR). Electroconvulsive shock (ECS), scopolamine administration, and acute hypoxia in a hermetic chamber were used as amnesic effects. Testing for the safety of CPAR was performed 24 h after amnesic exposure. The new substances, reference drug mexidol, and a 0.9% sodium chloride solution (control group) were administered once intraperitoneally 60 min before mice training. Results and discussion: Three of the five new nicotinic acid derivatives, LKhT 4-19 (100 mg/kg), LKhT 6-19 (25, 50, and 100 mg/kg), and LKhT 7-19 (100 mg/kg), have antiamnestic properties on models of amnesia in mice induced by ESC, scopolamine, and acute hypoxia in a hermetic chamber. At the same time, the most efficient substance – LKhT 6-19 – exceeds the reference drug mexidol on all three models used. In addition, this compound is also more efficient than two other new compounds, LKhT 4-19 and LKhT 7-19, on the model of ESC-induced amnesia and LKhT 7-19 on the scopolamine-induced amnesia model. Conclusion: Compound LKhT 6-19 is promising for further advanced preclinical studies as a potential drug with antiamnestic activity. Graphical abstract:

show abstract

Section: Introductionmentioning

confidence: 99%